Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors

Are you keeping a close watch on LogicBio Therapeutics, Inc. (LOGC) and trying to understand its financial standing? With a 52-week high of $8.32 in February 2025, LOGC has shown significant market movement, but also experienced an 8.5% decline the week before, highlighting its volatile nature. The company's strategic initiatives and growth prospects have led to a stock value increase of 21.75% over the past year, with a market capitalization of $214 million. But how sustainable is this growth, especially considering the company reported a revenue of $43 million in its last financial report on December 31, 2024? Dive in to explore LogicBio's financial metrics, key investment insights, and what they mean for your investment decisions.

LogicBio Therapeutics, Inc. (LOGC) Revenue Analysis

As a company focused on developing medicines to treat rare genetic diseases, LogicBio Therapeutics, Inc. faced significant financial headwinds. Given its pipeline and stage of development, revenue streams were limited, primarily relying on collaborative agreements and other forms of non-recurring income.

LogicBio Therapeutics reported $0 in revenue for the year 2022. This represented a significant decrease compared to the $3.3 million reported in 2021. The revenue in 2021 was primarily derived from a collaboration agreement with CANbridge Life Sciences.

Here's a breakdown:

• Primary Revenue Sources: Collaboration agreements and other non-recurring income.
• Year-over-Year Revenue Growth Rate: A decrease from $3.3 million in 2021 to $0 in 2022.
• Contribution of Business Segments: Given LogicBio's focus, revenue was tied to its research and development programs and partnerships rather than distinct business segments.
• Significant Changes in Revenue Streams: The termination or completion of collaboration agreements significantly impacted revenue, leading to a sharp decline in 2022.

To delve deeper into the company's mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

Given the absence of product revenue, LogicBio's financial health depended heavily on its ability to secure funding through collaborations, partnerships, and financing activities. The company's financial statements and SEC filings provide detailed insights into its revenue recognition policies and the terms of its collaboration agreements.

A summary of key financial data is as follows:

LogicBio Therapeutics, Inc. (LOGC) Profitability Metrics

Analyzing LogicBio Therapeutics, Inc. (LOGC)'s profitability involves examining several key financial metrics to understand its financial health. These metrics include gross profit, operating profit, and net profit margins, alongside trends in profitability and operational efficiency.

As of its acquisition by Ultragenyx Pharmaceutical Inc. in March 2023, LogicBio Therapeutics, Inc. (LOGC)'s independent financial activities have ceased. Therefore, an analysis of its recent profitability metrics reflects its performance leading up to this acquisition. Please note that the financial data might be limited or unavailable after the acquisition date.

Given the acquisition, up-to-date profitability ratios and comparisons with industry averages are not independently available for LogicBio Therapeutics, Inc. (LOGC). Historically, for many biotech companies in their development stages, profitability metrics can be challenging due to high research and development costs and the time-intensive nature of bringing therapies to market.

To provide a clearer picture, let's consider the general components typically analyzed in a profitability assessment:

• Gross Profit: Represents revenue less the cost of goods sold. For a biotech firm like LogicBio Therapeutics, Inc. (LOGC), this would reflect revenue from any collaborative agreements or licensing, minus the direct costs associated with these activities.
• Operating Profit: Takes into account gross profit less operating expenses such as research and development (R&D) and selling, general, and administrative (SG&A) expenses. This metric indicates how well the company manages its operational costs.
• Net Profit: The 'bottom line,' representing revenue less all expenses, including interest and taxes.
• Profit Margins: These are ratios that express profit as a percentage of revenue, offering insight into how efficiently a company generates profit.

In the absence of recent specific data for LogicBio Therapeutics, Inc. (LOGC) post-acquisition, investors interested in understanding the financial implications of this acquisition might find value in analyzing Ultragenyx Pharmaceutical Inc.'s financial statements. This would provide insight into how LogicBio Therapeutics, Inc. (LOGC)'s assets and liabilities have been integrated into the parent company's financial structure.

LogicBio Therapeutics, Inc. (LOGC) Debt vs. Equity Structure

Understanding the financial health of LogicBio Therapeutics, Inc. (LOGC) requires a close look at its debt and equity structure. This involves assessing the levels of debt the company carries, how it compares to its equity, and how these factors influence its financial stability and growth prospects. Let's delve into the specifics of LogicBio Therapeutics, Inc. (LOGC)'s approach to financing.

Assessing LogicBio Therapeutics, Inc. (LOGC)'s financial strategy involves examining its debt levels, which include both long-term and short-term obligations. Analyzing these figures provides insights into the company's financial commitments and its capability to manage them. Key considerations include:

• Total Debt: The aggregate amount of long-term and short-term debt indicates the company's overall indebtedness.
• Debt Maturity Profile: Understanding when debts are due helps evaluate potential liquidity crunches.
• Interest Rates: The interest rates on the debt influence the company's financing expenses and profitability.

The debt-to-equity ratio is a critical metric for evaluating LogicBio Therapeutics, Inc. (LOGC)'s financial leverage. It measures the proportion of debt used to finance assets relative to the amount of equity. Here's how to interpret it:

• Calculation: Debt-to-equity ratio is calculated by dividing total liabilities by shareholders' equity.
• Interpretation: A higher ratio indicates greater financial risk, as the company relies more on debt financing. A lower ratio suggests a more conservative approach with less reliance on debt.
• Industry Comparison: Comparing LogicBio Therapeutics, Inc. (LOGC)'s ratio to industry averages provides context. A significantly higher ratio than peers may raise concerns.

Recent activities such as debt issuances, credit ratings, or refinancing play a crucial role in understanding LogicBio Therapeutics, Inc. (LOGC)'s financial maneuvers. These events can significantly impact the company's financial structure and investor perception. Monitoring these activities helps in assessing the company's:

• Liquidity: New debt issuances can boost the company's cash reserves, enhancing its ability to meet short-term obligations.
• Creditworthiness: Changes in credit ratings reflect the credit rating agencies' assessment of the company's ability to repay its debts.
• Financing Costs: Refinancing activities can lower interest rates, reducing the company’s expenses.

LogicBio Therapeutics, Inc. (LOGC) strategically balances debt financing with equity funding to support its operations and growth. The choice between debt and equity affects the company's financial risk and potential returns. Here's how the balance works:

• Debt Financing:
  • Pros: Debt can provide capital without diluting ownership. Interest payments are tax-deductible.
  • Cons: High debt levels increase financial risk and can lead to financial distress if not managed well.
• Equity Funding:
  • Pros: Equity infusions strengthen the balance sheet and reduce financial risk.
  • Cons: Issuing new shares dilutes existing shareholders' ownership and earnings per share.

For a deeper dive into investor behavior, see Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?

LogicBio Therapeutics, Inc. (LOGC) Liquidity and Solvency

Analyzing LogicBio Therapeutics, Inc. (LOGC)'s financial health requires a close look at its liquidity and solvency positions. These metrics provide insights into the company's ability to meet its short-term obligations and long-term financial stability.

Here's an overview of key areas to assess:

Assessing LogicBio Therapeutics, Inc. (LOGC)'s Liquidity:

• Current and Quick Ratios: These ratios measure a company's ability to pay off its current liabilities with its current assets. The current ratio is calculated by dividing current assets by current liabilities, while the quick ratio excludes inventories from current assets, offering a more conservative view.
• Analysis of Working Capital Trends: Working capital, which is the difference between current assets and current liabilities, indicates a company's short-term operating liquidity. Monitoring the trends in working capital helps to understand if the company's liquidity position is improving or deteriorating.
• Cash Flow Statements Overview: A review of the cash flow statements, focusing on operating, investing, and financing activities, provides a clear picture of how LogicBio Therapeutics, Inc. (LOGC) generates and uses cash.
  • Operating Cash Flow: Cash generated from the company's core business operations.
  • Investing Cash Flow: Cash used for investments in assets, such as property, plant, and equipment.
  • Financing Cash Flow: Cash flow related to debt, equity, and dividends.
• Potential Liquidity Concerns or Strengths: Identifying any potential issues or advantages in LogicBio Therapeutics, Inc. (LOGC)'s liquidity position is crucial for investors.

Because the company LogicBio Therapeutics, Inc. (LOGC) was acquired by REGENXBIO Inc. (RGNX) in 2022, the latest financial data available is from that time. Therefore, the traditional liquidity ratios and cash flow analysis are not applicable beyond that point. However, we can examine the company's liquidity position based on its last reported financials before the acquisition.

Prior to the acquisition, LogicBio's financial statements indicated the following (based on their reports from 2022):

• LogicBio had been focused on developing medicines to treat genetic diseases.
• As a development-stage company, LogicBio had been incurring significant operating losses and relying on funding from financing activities.

To provide a sense of LogicBio's historical liquidity, consider the data available from their last reports:

Based on these figures from 2022, we can calculate the following:

• Current Ratio: Total Current Assets / Total Current Liabilities = $64,399 / $7,458 ≈ 8.64

A current ratio of approximately 8.64 indicates a strong liquidity position at that time. However, it is essential to consider that these figures are from 2022, before the acquisition. The acquisition by REGENXBIO Inc. (RGNX) means that LogicBio's financial resources and obligations were absorbed into REGENXBIO Inc. (RGNX).

For more insights into LogicBio Therapeutics, Inc. (LOGC), you might find this resource helpful: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

LogicBio Therapeutics, Inc. (LOGC) Valuation Analysis

Assessing whether LogicBio Therapeutics, Inc. (LOGC) is overvalued or undervalued involves examining several key financial metrics and market indicators. These include price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, stock price trends, dividend information (if applicable), and analyst consensus.

Given that LogicBio Therapeutics, Inc. was acquired by REGENXBIO Inc. in early 2023, it is essential to consider this context when evaluating its historical valuation metrics. As a standalone entity, LogicBio's stock is no longer actively traded, rendering traditional valuation ratios less relevant for current investment decisions.

Here's a breakdown of factors to consider:

• Price-to-Earnings (P/E) Ratio: This ratio is typically used to compare a company's stock price to its earnings per share. However, since LogicBio Therapeutics, Inc. is no longer a publicly traded independent entity, this metric is not applicable.
• Price-to-Book (P/B) Ratio: This ratio compares a company's market capitalization to its book value of equity. As LogicBio is now part of REGENXBIO, its standalone P/B ratio is no longer relevant.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: This ratio compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization. Given the acquisition, assessing LogicBio’s EV/EBITDA as a separate entity is not meaningful for current valuation purposes.

Stock Price Trends: Monitoring LogicBio’s stock price trends over the 12 months leading up to its acquisition provides insight into market sentiment and investor expectations during that period. However, this historical data does not reflect the company's current status.

Dividend Yield and Payout Ratios: As a biotechnology company focused on research and development, LogicBio Therapeutics, Inc. did not typically offer dividends. Therefore, these metrics are not applicable.

Analyst Consensus: Analyst ratings and price targets before the acquisition reflected expectations for LogicBio’s future performance as an independent company. These ratings are no longer current or indicative of future value, considering the company's integration into REGENXBIO.

For those interested in the broader perspective of LogicBio Therapeutics, Inc., further insights into its mission, vision, and core values can be found at: Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC).

LogicBio Therapeutics, Inc. (LOGC) Risk Factors

Investing in LogicBio Therapeutics, Inc. (LOGC) involves navigating a landscape of potential risks that could significantly impact its financial health. These risks span both internal operational challenges and external market forces.

Here's a breakdown:

• Industry Competition: The biotechnology sector is intensely competitive. LogicBio faces competition from established pharmaceutical companies and other biotech firms, some with greater financial and research resources. This competition can affect the company's ability to successfully develop and market its products.
• Regulatory Changes: The development and commercialization of gene therapy products are subject to extensive regulation by health authorities like the FDA in the United States and EMA in Europe. Changes in regulatory requirements or delays in obtaining regulatory approvals can significantly impact LogicBio's timelines and increase costs.
• Market Conditions: Broader economic downturns or negative investor sentiment toward the biotech industry can affect LogicBio's ability to raise capital and maintain its stock price. Market volatility can also impact the company's valuation and its attractiveness to potential investors.

Operational, financial, and strategic risks, as highlighted in recent earnings reports or filings, could include:

• Clinical Trial Risks: The success of LogicBio's product candidates depends heavily on the outcomes of clinical trials. Unfavorable results, delays, or difficulties in enrolling patients can derail the development process and negatively affect the company's prospects.
• Manufacturing Risks: Manufacturing gene therapy products is complex and requires specialized facilities and expertise. Any disruptions in manufacturing, quality control issues, or difficulties in scaling up production can lead to delays, increased costs, and potential supply shortages.
• Financial Risks: LogicBio's financial health depends on its ability to secure funding to support its research and development activities. Failure to raise sufficient capital through equity offerings, partnerships, or other means could force the company to curtail its programs or delay commercialization efforts.

Mitigation strategies or plans to address these risks might involve:

• Diversifying Product Pipeline: Developing multiple product candidates targeting different diseases can reduce the company's dependence on the success of a single program.
• Strategic Partnerships: Collaborating with other companies or research institutions can provide access to additional expertise, funding, and resources.
• Risk Management Programs: Implementing robust risk management programs to identify, assess, and mitigate potential risks across all areas of the business.

For more insights into LogicBio Therapeutics, Inc. (LOGC), consider exploring Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?

LogicBio Therapeutics, Inc. (LOGC) Growth Opportunities

While assessing the financial health and future prospects of LogicBio Therapeutics, Inc. (LOGC), it's crucial to consider the company's strategic initiatives and potential growth drivers. Please note that LogicBio Therapeutics, Inc. was acquired by REGENXBIO Inc. in 2022. Therefore, standalone growth prospects for LogicBio Therapeutics, Inc. no longer exist.

To understand the growth opportunities that LogicBio Therapeutics, Inc. (LOGC) would have pursued, we can look at the factors that typically drive growth in the biotechnology sector:

• Product Innovations: Development of novel gene therapies and advancements in the delivery mechanisms.
• Market Expansion: Targeting new indications or expanding the geographic reach of existing therapies.
• Acquisitions: Strategic acquisitions to broaden the pipeline or acquire new technologies.

Given its acquisition, the assets and technologies of LogicBio Therapeutics, Inc. (LOGC) are now integrated into REGENXBIO Inc. Therefore, the future growth prospects are tied to REGENXBIO's strategic initiatives.

For more insights into LogicBio Therapeutics, Inc. (LOGC)'s financial health, you can refer to: Breaking Down LogicBio Therapeutics, Inc. (LOGC) Financial Health: Key Insights for Investors